BioCentury
ARTICLE | Clinical News

NVR-1221: Phase Ia data

November 24, 2014 8:00 AM UTC

A Phase Ia trial in 40 healthy adults ages 18-65 showed that single oral doses of 50, 150, 400 and 800 mg NVR-1221 and twice-daily doses of 200 mg NVR-1221 for 14 days were well tolerated with no seri...